Overview

HEALEY ALS Platform Trial - Regimen C CNM-Au8

Status:
Enrolling by invitation

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen C will evaluate the safety and efficacy of a single study drug, CNM-Au8, in participants with ALS.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Merit E. Cudkowicz, MD

Collaborator:

Clene Nanomedicine